Macrolide-resistant Bordetella pertussis strain identified during an ongoing epidemic, Finland, January to October 2024

Milja Miettinen; Alex-Mikael Barkoff; Aino Nyqvist; Carita Savolainen-Kopra; Jenni Antikainen; Jussi Mertsola; Lauri Ivaska; Qiushui He

doi:10.2807/1560-7917.ES.2024.29.49.2400765

Macrolide-resistant Bordetella pertussis strain identified during an ongoing epidemic, Finland, January to October 2024

Milja Miettinen
, Alex-Mikael Barkoff
, Aino Nyqvist
, Carita Savolainen-Kopra
, Jenni Antikainen
, Jussi Mertsola
, Lauri Ivaska
, Qiushui He

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Abstrakti

Since April 2024, a pertussis epidemic has been ongoing in Finland with 2,215 notified cases by end October. Of them, 30.1% (n = 667) were aged 10-14 years. Of the 462 Bordetella pertussis isolates characterised, one was macrolide-resistant (minimum inhibitory concentration (MIC) of erythromycin, azithromycin and clarithromycin >256 μg/mL). The resistant isolate was serotype FIM2, vaccine antigen pertactin-deficient and harboured ptxP3 allele. The emergence of macrolide-resistant B. pertussis in Europe is worrisome and its rapid identification is important.

Alkuperäiskieli	englanti
Artikkeli	2400765
Lehti	Eurosurveillance
Vuosikerta	29
Numero	49
Sivumäärä	6
ISSN	1025-496X
DOI - pysyväislinkit	https://doi.org/10.2807/1560-7917.ES.2024.29.49.2400765
Tila	Julkaistu - 5 jouluk. 2024
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Lisätietoja

Publisher Copyright:
© 2024 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

Tieteenalat

3111 Biolääketieteet

Pääsy asiakirjaan

10.2807/1560-7917.ES.2024.29.49.2400765

eurosurv-29-49-1Lopullinen julkaistu versio, 359 KBLisenssi: CC BY

Siteeraa tätä

@article{429548a48b3d4d2cb2a355eeecc38b02,

title = "Macrolide-resistant Bordetella pertussis strain identified during an ongoing epidemic, Finland, January to October 2024",

abstract = "Since April 2024, a pertussis epidemic has been ongoing in Finland with 2,215 notified cases by end October. Of them, 30.1\% (n = 667) were aged 10-14 years. Of the 462 Bordetella pertussis isolates characterised, one was macrolide-resistant (minimum inhibitory concentration (MIC) of erythromycin, azithromycin and clarithromycin >256 μg/mL). The resistant isolate was serotype FIM2, vaccine antigen pertactin-deficient and harboured ptxP3 allele. The emergence of macrolide-resistant B. pertussis in Europe is worrisome and its rapid identification is important.",

keywords = "3111 Biomedicine",

author = "Milja Miettinen and Alex-Mikael Barkoff and Aino Nyqvist and Carita Savolainen-Kopra and Jenni Antikainen and Jussi Mertsola and Lauri Ivaska and Qiushui He",

year = "2024",

month = dec,

day = "5",

doi = "10.2807/1560-7917.ES.2024.29.49.2400765",

language = "English",

volume = "29",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control ",

number = "49",

}

TY - JOUR

T1 - Macrolide-resistant Bordetella pertussis strain identified during an ongoing epidemic, Finland, January to October 2024

AU - Miettinen, Milja

AU - Barkoff, Alex-Mikael

AU - Nyqvist, Aino

AU - Savolainen-Kopra, Carita

AU - Antikainen, Jenni

AU - Mertsola, Jussi

AU - Ivaska, Lauri

AU - He, Qiushui

PY - 2024/12/5

Y1 - 2024/12/5

N2 - Since April 2024, a pertussis epidemic has been ongoing in Finland with 2,215 notified cases by end October. Of them, 30.1% (n = 667) were aged 10-14 years. Of the 462 Bordetella pertussis isolates characterised, one was macrolide-resistant (minimum inhibitory concentration (MIC) of erythromycin, azithromycin and clarithromycin >256 μg/mL). The resistant isolate was serotype FIM2, vaccine antigen pertactin-deficient and harboured ptxP3 allele. The emergence of macrolide-resistant B. pertussis in Europe is worrisome and its rapid identification is important.

AB - Since April 2024, a pertussis epidemic has been ongoing in Finland with 2,215 notified cases by end October. Of them, 30.1% (n = 667) were aged 10-14 years. Of the 462 Bordetella pertussis isolates characterised, one was macrolide-resistant (minimum inhibitory concentration (MIC) of erythromycin, azithromycin and clarithromycin >256 μg/mL). The resistant isolate was serotype FIM2, vaccine antigen pertactin-deficient and harboured ptxP3 allele. The emergence of macrolide-resistant B. pertussis in Europe is worrisome and its rapid identification is important.

KW - 3111 Biomedicine

U2 - 10.2807/1560-7917.ES.2024.29.49.2400765

DO - 10.2807/1560-7917.ES.2024.29.49.2400765

M3 - Article

C2 - 39639816

AN - SCOPUS:85211756211

SN - 1025-496X

VL - 29

JO - Eurosurveillance

JF - Eurosurveillance

IS - 49

M1 - 2400765

ER -